期刊文献+

异丙基肾上腺素心力衰竭大鼠醛固酮的改变 被引量:3

Change of plasma aldosterone in rats with ISO-induced congestive heart failure
在线阅读 下载PDF
导出
摘要 目的建立异丙基肾上腺素诱导SD大鼠充血性心力衰竭模型,观察血清醛固酮的变化。方法用ISO(170 mg/kg)对SD大鼠皮下注射2次,建立大鼠充血性心力衰竭模型,在造模后18周进行血流动力学检测左室舒张末压力、左室内压峰值、左心室压力上升/下降最大速率及心率,取血检测醛固酮,并取心肌观察病理形态学特征。结果与正常对照组相比,模型组大鼠心率及左室舒张末压力明显增加(P<0.01),左室内压峰值、左心室压力上升/下降最大速率明显下降(P<0.01),左心室重量指数明显增加(P<0.01),醛固酮显著升高(P<0.01)。光学显微镜结果显示,异丙基肾上腺素组大鼠心肌细胞肥大,部分心肌细胞有嗜酸变性和/或坏死,心肌间质结缔组织增生。结论应用大剂量异丙基肾上腺素诱导大鼠充血性心力衰竭模型,该作用可能与血浆ALD升高有关。 Objective To establish the animal model of isoproterenol (ISO)- induced congestive heart failure (CHF) in rats and study the changes of serum aldosterone. Methods Male Sprague- Dawley rats were randomly allocated to the ISO- induced chronic heart failure group (ISO group, n=50) treated with two subcutaneous injections of ISO and the healthy control group (CON group, n= 10) treated with two subcutaneous injections of normal saline. At the 18th week, the left ventricular end diastolic pressure, left ventricular end diastolic pressure, maximal rate of LV pressure rise/decline and heart rate were assessed. Aldosterone (ALD) in plasma was detected. 18 weeks later, the mass ratio of heart ventricle and left ventricle to body was measured. Results Compared with that in CON group, the LVEF, FS significantly decreased and the LVEDD, LVESD in ISO group enlarged notably (P〈0.01). The mass ratio of left ventricle to body and the concentration of ALD of ISO group increased distinctly (P〈0. 01), compared with that of CON group. Conclusion Activation of plasma aldosterone is increased in high-dose isoproterenol- induction rat model of CHF.
出处 《西部医学》 2010年第4期595-598,共4页 Medical Journal of West China
基金 南京军区南京总医院科研基金资助项目(批准号:Q2008042)
关键词 异丙基肾上腺素 SD大鼠 充血性心力衰竭 醛固酮 心室重构 Isoproterenol SD Rats Congestive heart failure Aldosterone Myocardial Remodeling
作者简介 通讯作者:蔡辉,Emall:gh.yz.js.chn@163.com
  • 相关文献

参考文献14

  • 1李为民,田颖,孔一慧,甘润韬,孙桂芳,沈景霞.异丙基肾上腺素致大鼠心力衰竭模型的实验研究[J].哈尔滨医科大学学报,2003,37(5):386-388. 被引量:45
  • 2Rona G,Chappel GI,Balazs T,et al.An infarct-like myo-cardial lesion and other toxic manifestations p roduced by isopro-terenol in the rat[J].Arch Pathol,1959,67,443-455.
  • 3Whitmarsh AJ,Davis RJ.Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction path-ways[J].J Mol Med,1996,74(10):589-607.
  • 4Lemarie CA,Paradis P,Schiffrin EL.New insights on signaling cascades induced by cross-talk between angiotensin Ⅱ and aldo-sterone[J].J Mol Med,2008,86(6),673-678.
  • 5Weber KT.Aldosterone in congestive heart failure[J].N Engl J Med,2001,345(23):1689-1697.
  • 6王霞娟,卜瑞芳,邓振霞.醛固酮与糖尿病及其慢性并发症的关系[J].医学研究生学报,2007,20(5):548-552. 被引量:14
  • 7Johar S.Cave ACNarayanapanicker A,et al.Aldosterone mediates angiotensin II -induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase[J].Faseb J,2006,20(9),1546-1548.
  • 8Nakahara T.Takata Y.Hirayama Y,et al.Left ventricular hy-pertrophy and geometry in untreated essential hypertension is associated with blood levels of aldosterone and procollagen type DI amino-terminal peptide[J].Circ J,2007,71(5),716-721.
  • 9Montezano AC,Callera GE,Yogi A,et al.Aldosterone and angiotensin II synergistieally stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways[J].Arterioscler Thromb Vase Biol,2008,28 (8),1511-1518.
  • 10Rastogi S,Mishra S,Zaca V,et al.Effect of long-term mono-therapy with the aldosterone receptor blocker eplerenone on cy-toskeletal proteins and matrix metalloproteinases in dogs with heart failure[J].Cardiovasc Drugs Ther,2007,21 (6),415-422.

二级参考文献30

  • 1孙晓健,侯晓菲,刘少荣,刘文波,陶志刚,李建远.醛固酮合成酶基因-344T/C多态性与山东省汉族人原发性高血压相关性[J].中华医学遗传学杂志,2004,21(5):502-504. 被引量:33
  • 2夏正坤,祁建胜,刘光陵.血管紧张素Ⅱ受体拮抗剂在IgA肾病中的临床应用[J].医学研究生学报,2005,18(5):451-453. 被引量:5
  • 3Takebayashi K,Matsumoto S,Aso Y,et al.Aldosterone blockadc attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy[J].J Clin Endocrinol Metab,2006,91 (6):2214-2217.
  • 4Cha DR,Kang YS,Han SY,et al.Role of aldosterone in diabetic nephropathy[J].Nephrology,2005,10(Suppl):S37-39.
  • 5Delyani JA.Mineralocorticoid receptor antagonists:The evolution of utility and pharmacology[J].Kidney Int,2000,57(4):1408-1411.
  • 6Pitt B,Zannad F,Remme WJ,et al.for the Randomized Aldactone Evaluation Study:The effect of spironolactone on morbidity and mortality in patients with severe heart failure[J].N Engl J Med,1999,341 (10):709-717.
  • 7Pitt B,Remme W,Zannad F,et al.For the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators:Eplerenone,a selective aldosterone blocker,in patients with left ventricular dysfunction after myocardial infarction[J].N Engl J Med,2003,348(14):1309-1321.
  • 8Smith SC Jr,Allen J,Blair SN,et al.AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease:2006 update:endorsed by the National Heart,Lung,and Blood Institute[J].Circulation,2006,113(19):2363-2372.
  • 9Schjoedt KJ,Jacobsen P,Rossing K,et al.Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy:the role of aldosterone[J].Horm Metab Res,2005,37(Suppl 1):4-8.
  • 10Epstein M.Aldosterone receptor blockade and the role of eplerenone:Evolving perspectives[J].Nephrol Dial Transplant,2003,18 (10):1984-1992.

共引文献57

同被引文献21

引证文献3

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部